Catheter Precision, Inc. announced on August 28, 2025, the successful completion of the first LockeT procedures in France. These procedures were performed at CHU Rennes, led by Professor Raphael Martins and his team.
This milestone represents significant progress in the adoption and commercialization of LockeT across Europe, following the device's CE Mark approval. CHU Rennes is also a commercial partner for the company’s VIVO product line.
Fatih Ayoglu, Sales Manager for EMEA & APAC, stated that completing product evaluations so soon after receiving the CE Mark is a testament to the market need for a product like LockeT. The company looks forward to expanding its commercial footprint in the region.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.